Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk (NYSE:NVO) presented the full results from its SELECT cardiovascular trial at an American Heart Association (AHA) meeting on Saturday and analysts at Bank of America (BofA) Securities said they were more favorable than expected. In a note to clients, the analysts said Nova's cardiovascular (CV) trial provides another “feather in weight-loss drugs cap,” creating a favorable set-up for Eli Lilly and Co (NYSE:LLY) and its CV outcomes trial, SURMOUNT-MMO.

Eli Lilly rides on Novo's coattails as BofA analysts maintain ‘Buy' rating following SELECT trial data

Pharmaceutical giant Eli Lilly's experimental vaccine-like drug slashed a risk factor for heart disease by a whopping 94% for almost a year, according to a report.

Eli Lilly's experimental drug lowers risk of heart disease by 94%: study

Eli Lilly and Co (NYSE:LLY)'s experimental therapy lepodisiran reduced the harmful risk factor for lipoprotein (a) by up to 94% for up to a year with just a single dose, data from a first-in-human trial has shown. Lipoprotein (a) is a form of cholesterol that is a genetic risk factor for a range of conditions including coronary artery disease, stroke, and thrombosis.

Eli Lilly's experimental heart drug cuts genetic risk factor by 94% for a year

AbbVie

Johnson & Johnson

Novo Nordisk

Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), J&J (JNJ) and AbbVie (ABBV) are worth retaining in your portfolio.

4 Large Drug Stocks Likely to Sail Through Industry Woes

JPMorgan Chase & Co

Taiwan Semiconductor Manufacturing

Visa

The magnificent seven stocks have captured a lot of investor attention and investment in 2023. Those seven tech firms have been responsible for a great portion of the overall market rebound this year.

The Magnificent Seven: 7 Stocks That Could Make It the ‘Elite Eight'

Novo Nordisk's weight management blockbuster produced some surprising results for its ability to reduce patients' risk of a second heart attack. The Food and Drug Administration recently approved Eli Lilly's weight management drug Zepbound.

Better Buy Now: Novo Nordisk vs. Eli Lilly

Eli Lilly's anti-obesity drug Zepbound (tirzepatide) receives approval in the US and recommended approval in the EU. The SELECT study data shows that semaglutide 2.4 mg reduces major adverse cardiovascular events and has additional benefits such as weight loss. The anti-obesity drug class is projected to generate $150 billion in US revenues by 2030, with injectables being the primary choice for the next 18 months. Oral medications are expected to be approved in 2025-2026.

Eli Lilly: Favorable Developments Continue Regarding Anti-Obesity Drug Franchise

Eli Lilly and Company (NYSE:LLY ) UBS Biopharma 2023 Conference November 8, 2023 3:00 PM ET Company Participants Patrik Jonsson - President, Lilly Immunology Conference Call Participants Trung Huynh - UBS Trung Huynh Okay. We're at the hour now.

Eli Lilly and Company (LLY) Presents at UBS Biopharma 2023 Conference (Transcript)

Eli Lilly just gained approval for a drug that could win big in the multibillion-dollar weight-loss market. Johnson & Johnson is focusing on its high-growth businesses after the recent spinoff of its consumer health unit.

Cautious Investor? 2 Safe Stocks You Also Can Count on For Growth

Eli Lilly (LLY) stock price movement has experienced a whirlwind since Wednesday's approval of its diabetes medication, Tirzepatide, for chronic weight management in the United States and the United Kingdom. The stock, took a dive on Thursday to close at $591.49 after enjoying a surge on Wednesday especially following the approval by the US FDA.

Eli Lilly's Tirzepatide approved in the EU days after US and UK approval

As part of the MarketWatch 50 series, Eleanor Laise interviewed Dr. Daniel Skovronsky, the chief scientific and medical officer at Eli Lilly & Co. LLY, +0.11%. The company's stock has soared 63% this year amid excitement for its Mounjaro treatment for Type 2 diabetes.

Here's how Eli Lilly might bring a game-changing Alzheimer's drug to market

Fair Isaac

At 3.7%, inflation remains an issue. While consumer prices have come down from their peak of 9.1% in June 2022, the inflation rate in the U.S. remains well above the Federal Reserve's 2% annualized target.

3 Stocks to Buy for Retirees Looking to Beat Inflation

Abbott Labs

AstraZeneca

Anheuser-Busch InBev

Crown Hlds

Chipotle

DoorDash

Darden Restaurants

Fresenius Medical Care

Hershey

Keurig Dr Pepper Inc

Mondelez

PepsiCo

Teleflex

That's the message from many corporate executives who have lately been peppered with questions about how Wegovy, Ozempic and other drugs widely used for weight loss may impact their bottom line.

Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.

Europe's medicines regulator said on Friday its committee had recommended changing authorization terms for Eli Lilly's drug Mounjaro to include weight-management.

EU regulator backs Eli Lilly's Mounjaro for weight management

Biogen

Roche Holding AG

There's now more than one medicine on the market to treat Alzheimer's disease. Safety and efficacy will be the two major areas of future competition.

The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?

Eli Lilly & Co. NYSE: LLY reversed lower on November 9. This came after LLY stock advanced 3.20% after the company got regulators' OK for its weight-loss drug Zepbound.

Will Eli Lilly's Zepbound be the next big weight-loss drug?

Britain's drug regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), on Friday confirmed that it is reviewing a new injection pen that Eli Lilly plans to use for the U.S. drugmaker's Mounjaro drug against obesity and diabetes.

British regulator confirms review of new pen for Lilly's Mounjaro drug

Eli Lilly just won FDA approval for Zepbound (tirzepatide) as a chronic weight management treatment. Zepbound should generate huge sales over the coming years.

Look Out, Ozempic and Wegovy: Eli Lilly Has a New Weight-Loss Drug in Town

Eli Lilly set some ambitious goals for 2023, highlighting a promising mix of assets in its portfolio. The company has obtained multiple drug approvals this year.

Eli Lilly Was Hoping for 5 Big Drug Launches This Year. Here's How It Has Done Thus Far.

Eli Lilly says its obesity drug's list price is about 20% lower than Novo's Wegovy.

Lilly Takes First Jab in Obesity Drug Showdown

Eli Lilly received FDA approval to sell tirzepatide for obesity treatment, expanding its market beyond diabetes. Shares of Eli Lilly jumped 3.2% on the news, resulting in a $17.3 billion increase in shareholder wealth. Tirzepatide has shown promising results in clinical trials, with patients losing an average of 48 pounds over 72 weeks.

Eli Lilly's Big Win In The Obesity Space Just Got Bigger

The FDA approved Lilly's Zepbound (tirzepatide) for chronic weight loss management. Today's decline appears to be a case of investors "buying the rumor and selling the news.

Why Eli Lilly Stock Is Slumping Today

Axsome Therapeutics

Transmedics Group Inc

Eli Lilly's strong prospects have given investors plenty of reason to remain bullish despite rising interest rates. Axsome has gone from reporting no sales to now having a couple of strong, revenue-generating assets.

3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest Rates

Eli Lilly is eager to steal market share from Novo Nordisk's drug Ozempic. Creating medicines that don't have certain side effects is one strategy.

Eli Lilly Has Yet Another Ozempic Killer in the Works. Is It a Screaming Buy?

Eli Lilly on Thursday said it has not yet gained approval in Britain for the injection pen it plans to use for its Mounjaro drug against obesity and diabetes, adding to uncertainty over timing of the product's launch.

News for Eli Lilly Stock (LLY)